Zai Lab Limited (ZLAB) Prcies 5.5M ADS Offering at $47.50/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
January 22, 2020 9:44 PM ESTSHANGHAI, China, and SAN FRANCISCO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 5,500,000 American depositary shares (ADSs), each representing one ordinary share of the Company (the Primary ADS Offering), at a price of US$47.50 per ADS. In addition, QM11 Limited, a shareholder of the Company, is offering 500,000 ADSs of the Company (the Secondary ADS Offering and together with the Primary ADS Offering, the Offering) at the same price. The... More
